Age at diagnosis, stage and amplification of the N-myc proto-oncogene (MYCN) are clinical and molecular risk factors that the International Neuroblastoma Risk Group (INRG) utilized to classify patients into high, intermediate and low risk subgroups on which current therapeutic strategy is based. The gene discussed is MYCN; the disease is neuroblastoma.